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Abstract
Background: Organic cation transporters (OCTs) determine not only physiological processes but are also involved
in the cellular uptake of anticancer agents. Based on microarray analyses in hepatocellular carcinoma (HCC),
SLC22A1/OCT1 mRNA seems to be downregulated, but systematic protein expression data are currently missing.
Moreover, the underlying molecular mechanisms responsible for altered SLC22A1 expression in HCC are not fully
understood. Therefore, we investigated the role of DNA methylation in the transcriptional regulation of the family
members SLC22A1/OCT1, SLC22A2/OCT2 and SLC22A3/OCT3 in HCC.
Methods: Semiquantitative immunohistochemistry of SLC22A1 protein expression was performed in paired HCC
and histological normal adjacent liver tissues (n = 71) using tissue microarray analyses, and the results were
correlated with clinicopathological features. DNA methylation, quantified by MALDI-TOF mass spectrometry and
gene expression of SLC22A1, SLC22A2 and SLC22A3 were investigated using fresh-frozen HCC (n = 22) and non-
tumor adjacent liver tissues as well as histologically normal liver samples (n = 120) from a large-scale liverbank.
Results: Based on tissue microarray analyses, we observed a significant downregulation of SLC22A1 protein
expression in HCC compared to normal adjacent tissue (P < 0.0001). SLC22A1 expression was significantly inverse
correlated with expression of the proliferation marker MIB1/Ki-67 (rs = -0.464, P < 0.0001). DNA methylation of
SLC22A1 was significantly higher in HCC compared with non-tumor adjacent liver tissue and was lowest in
histologically normal liver tissue. Methylation levels for SLC22A1 in combination with RASSF1A resulted in a
specificity of > 90% and a sensitivity of 82% for discriminating HCC and tumor-free liver tissue.
Conclusions: DNA methylation of SLC22A1 is associated with downregulation of SLC22A1 in HCC and might be a
new biomarker for HCC diagnosis and prognosis. Moreover, targeting SLC22A1 methylation by demethylating
agents may offer a novel strategy for anticancer therapy of HCC.
Background
Hepatocellular carcinoma (HCC) is the sixth most com-
mon cancer worldwide and the third most common cause
of cancer-related death. Understanding of the molecular
pathogenesis of HCC has improved, and some progress
has been made in translating these findings into clinical
practice [1]. Therapeutic options include sorafenib, as first
effective systemic treatment against HCC, as well as
radioembolization and oncolytic approaches. Currently,
there are more than 150 ongoing clinical trials. But, in the
main, these are not integrating information about the
molecular pathogenesis of HCC [2]. For instance, the cel-
lular uptake of anticancer drugs is an important first step
in the mechanism of drug action. Therefore, multidrug
resistance can result not only from increased efflux but
also reduced uptake of drug into tumor cells. Uptake
transport in hepatocytes is mediated by members of the
solute carrier (SLC) family. Organic cation transporters
(OCTs) are involved in the transport of a variety of endo-
genous and exogenous organic cationic compounds and
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a significant determinant of physiological functions in dif-
ferent organs [3-5]. OCTs are also important drug targets
since several clinically relevant agents, including antican-
cer drugs (for example, platinum agents), are substrates of
OCTs.
Expression profiles among the three OCT family mem-
bers OCT1 (encoded by SLC22A1), OCT2 (SLC22A2)a n d
OCT3 (SLC22A3) are extremely diverse in different tissues
[6]. SLC22A1 is expressed mainly in normal human liver,
and SLC22A2 is predominately expressed in kidney
[3-5,7,8]. There is already evidence that OCTs are differ-
entially expressed in tumor tissues, and based on microar-
ray data, SLC22A1 mRNA expression is downregulated in
HCC [9-11]. However, systematic analyses of expression
of SLC22A1, SLC22A2 and SLC22A3 have not been per-
formed so far in HCC. Moreover, the underlying mechan-
isms responsible for altered expression of SLC22A1 in
HCC compared with normal liver are poorly understood.
Epigenetic alterations, including DNA methylation and
histone modifications, are important mechanisms in
tumorigenesis. DNA hypermethylation-induced tran-
scriptional silencing of tumor suppressor and DNA repair
genes is a frequent phenomenon [12]. There is already
proof of principle for the clinical value of methylation
markers for classification (for example, colorectal cancer
[13,14]), prognosis [15] and prediction of therapeutic
response [12]. Thus, identification of specific expression-
regulating core gene regions (that is, CpG dinucleotides)
in the promoter is essential. With respect to OCTs, there
is evidence that kidney-specific expression of SLC22A2 is
regulated by DNA methylation [16]. Currently there are
no data on whether downregulation of SLC22A1 in HCC
could be explained by hypermethylation of the SLC22A1
promoter. Elucidating the precise mechanism for down-
regulation of SLC22A1 in HCC is especially important
because it is possible to overcome gene silencing with
demethylating agents like decitabine, which opens new
therapeutic strategies for HCC.
Therefore, in the present study we performed systematic
immunohistochemical analysis of SLC22A1 protein in
well-characterized, paired HCC and corresponding non-
tumor tissues and correlated the results with clinicopatho-
logical data. We elucidated systematically the influence of
DNA methylation on the transcriptional regulation of
SLC22A1, SLC22A2 and SLC22A3 in HCC tissues and in
tissues in a large human liver bank.
Materials and methods
Tumor and non-neoplastic human tissues
An overview about different sample sets used in the pre-
sent study is given in Table S1 in Additional file 1. HCC
tissues and corresponding adjacent non-tumor liver tissues
from patients who underwent surgical resection between
2001 and 2007 were collected at the Department of Inter-
nal Medicine I, University Hospital Regensburg, Regens-
burg, Germany and used for tissue microarray analysis
(TMA), as previously described [17,18]. Detailed clinico-
pathological characteristics of patients (n = 71) are given
in Table S2 in Additional file 1. Additionally, paired fresh-
frozen HCC tissues (n = 15) and adjacent non-tumor liver
samples were obtained from the same institution [19]. As
additional samples, seven HCCs were obtained from Ori-
Gene (OriGene, Rockville, MD, USA) and re-examined by
a pathologist. The patient characteristics are summarized
in Table S3 in Additional file 1. Finally, as a control group,
120 histologically normal fresh-frozen liver tissues (IKP-
liverbank; Table S4 in Additional file 1) were investigated,
which were collected at the Department of General, Visc-
eral and Transplantation Surgery (Campus Virchow, Uni-
versity Medical Center Charité, Humboldt University
Berlin, Germany) as previously reported [20]. For systema-
tic expression profiling of SLC22A1, SLC22A2 and
SLC22A3 in normal and tumor tissues, commercial arrays
including cDNA from 381 human tissues normalized to
beta-actin were used (TissueScan, Origene technologies,
Rockville, MD, USA). The study conforms to the ethical
guidelines of the 1975 Declaration of Helsinki and was
approved by the ethics committee of the University Hospi-
tal Regensburg (Regensburg, Germany), by the ethics com-
mittee of University of Tuebingen (Tuebingen, Germany)
and the Charite (Berlin, Germany). Written informed con-
sent was provided by each patient.
RNA isolation and TaqMan analysis
Total RNA was extracted from HCCs and non-tumor tis-
sue using the mirVana™ miRNA Isolation Kit (Applied
Biosystems/Ambion, Austin, TX, USA). High quality liver
RNA was extracted as previously described [20], and only
high-quality RNA preparations with RNA Integrity Num-
ber (RIN) assignment (> 7), as determined by Agilent
Bioanalyzer (Nano LabChip Kit, Agilent Technologies,
Waldbronn, Germany), were used. Total RNA was used
for cDNA syntheses using the High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, Foster
City, CA, USA). mRNA expression was quantified by Taq-
Man technology (for details see additional methods in
Additional file 1).
Immunofluorescence microscopy of tissue samples
Localization of OCTs in liver and HCC tissues was ana-
lyzed by immunofluorescence confocal laser scanning
microscopy (for details see additional methods in Addi-
tional file 1).
HCC tissue microarray analysis
TMAs were processed as previously described [17,18].
SLC22A1 immunohistochemistry was performed using a
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peptide corresponding to the carboxy-terminal sequence
of human SLC22A1 as described previously [20]. Stain-
ing of SLC22A1 was performed according to the follow-
ing protocol: 5 μm TMA sections were transferred to
slides (Superfrost-Plus, Langenbrinck, Teningen, Ger-
many). Tissues were deparaffinized by passing the speci-
mens through xylene and rehydrated through serial
dilutions of ethanol (100%, 96% and 70%). Heat-induced
antigen retrieval was accomplished using a solution buf-
fer at pH 6.0 (Dako Cytomation, Glostrup, Sweden) for
30 minutes. Endogenous peroxidase was blocked with a
peroxidase blocker (0.03% H2O2; Dako Cytomation) for
10 minutes. Slides were incubated for 30 minutes at
room temperature with the primary antibody (OCT1/
KEN, dilution 1:2,000) in an antibody diluent (Dako
Cytomation). For negative control the primary antibody
was omitted. The REAL-HRP system (REAL Envision
Detection System, Rabbit/Mouse, Dako Cytomation) was
used for detection of the antibody binding before sec-
tions were counterstained with hematoxylin and
mounted. For semiquantitative immunohistochemical
assessment first, staining intensity was graded according
to the following scoring system: 0 = negative, 1 = low, 2
= medium and 3 = high. As previously described
[21,22], the final immunoreactivity score was calculated
by multiplication of the staining intensity score (0 to 3)
and the percentage of immunoreactive (stained) cells (0
to 100%), resulting in a numeric value of 0 to 300.
MIB1 was analyzed applying the anti-Ki-67 antibody
(clone MIB1, 1:10, final concentration of 5 μg/ml;
DAKO) to assess the MIB1/Ki-67 proliferation rate as
previously described [17]. Evaluation of the staining was
done by two investigators blinded to the patient
characteristics.
DNA methylation analysis
Quantitative DNA methylation analysis was performed
with matrix-assisted laser desorption ionization time-
of-flight mass spectrometry (MALDI-TOF MS; Seque-
nom, San Diego, CA, USA), as described in the addi-
tional methods in Additional file 1. Mass spectra were
acquired with the MassArray Compact MALDI-TOF
MS (Sequenom) and spectra methylation ratios were
analyzed using the Epityper 1.0 software (Sequenom).
Statistical methods
Statistical analyses were performed with R-2.13.0, PASW
Statistics 17.0.2 and GraphPadPrism 4.03 (GraphPad
Software Inc., La Jolla, CA, USA). Statistical significance
was defined as P < 0.05. For a detailed description, see
the additional methods in Additional file 1.
Results
Expression profiling of SLC22A1, SLC22A2, and SLC22A3 in
normal and tumor tissue
A comprehensive analysis using cDNAs from 381 human
tissue samples (Table S1 in Additional file 1) from 20 dif-
ferent tissues revealed that SLC22A1 mRNA is expressed
most prominently in normal liver and expressed at signif-
icantly lower levels in HCC tissues (P = 0.029; Figure 1A).
SLC22A2 transcripts were present in human kidney, but
almost absent in human normal liver, as well as in HCC
tissue. SLC22A3 transcripts were detectable in a variety
of human tissues, including human liver (Figure 1a), and
SLC22A3 expression did not differ significantly between
normal and tumor liver tissue.
Moreover, specific antibodies were used to detect
SLC22A1, SLC22A2 and SLC22A3 protein by immuno-
fluoresence confocal laser scanning microscopy in HCC
tumor tissue (n = 7 from HCC cohort 1; Tables S1 and
S3 in Additional file 1) and histologically normal liver tis-
sue (n = 5 from IKP-liverbank; Tables S1 and S4 in Addi-
tional file 1) derived from patients without HCC. In line
with previous data, only SLC22A1 and SLC22A3 were
detected in human liver [20]. In HCC tissue, SLC22A3
and, at a lower level, SLC22A1 proteins were detected.
SLC22A2 was not detected in either normal or HCC
tissue (Figure 1b).
Protein expression analysis of SLC22A1 in HCC
To systematically evaluate expression of SLC22A1 pro-
tein in HCC tissues, levels were analyzed by semi-quanti-
tative immunohistochemistry using TMA of HCC and
corresponding adjacent non-tumor tissues [17,18]. Inves-
tigation of SLC22A1 protein expression was informative
in 68 HCC and 67 adjacent tissues of this HCC study
population (set 1; for details see Tables S1 and S2 in
Additional file 1), because some of the cores on TMAs
were lost or damaged during processing of the TMAs.
The expression of SLC22A1 was determined by applying
an immunohistochemical score, as described in the
Materials and methods. Statistical analysis revealed sig-
nificantly lower SLC22A1 immunoreactivity in HCC tis-
sues compared with adjacent tissues (P < 0.0001; Figure
2a), irrespective of the presumed etiology of the HCC
(for example, hepatitis B virus or hepatitis C virus; a
paired comparison is shown in Figure S1 in Additional
file 1). Examples of different staining intensities (0 =
n e g a t i v e ,1=l o w ,2=m e d i u m ,3=h i g h )i nn o n - t u m o r
as well as in HCC tissue are shown in Figure 2b.
SLC22A1 expression in HCC tissues, when present, was
variable, ranging from at least 20 to 90% of the cells, and
showed a more diffuse pattern compared with non-
tumor tissue (Figure 2c). In addition, expression of
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Figure 1 Expression analysis in normal and tumor tissues. (a) SLC22A1, SLC22A2,a n dSLC22A3 mRNA expression in different human normal
and tumor tissues of the respective organs (TissueScan, Origene Technologies, Rockville, MD, USA) was quantified using TaqMan technology. (b)
SLC22A1/OCT1, SLC22A2/OCT2 and SLC22A3/OCT3 protein expression (green) was analyzed by confocal laser scanning microscopy in HCC
tumor tissue (n = 7) compared with histologically normal liver tissue (n = 5, IKP-liverbank) derived from patients without hepatocellular
carcinoma (HCC). Specific antibodies were used to detect SLC22A1, SLC22A2 and SLC22A3 proteins. Representative images are shown.
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Figure 2 Immunohistochemical staining of SLC22A1 protein in hepatocellular carcinoma and histological non-tumor adjacent tissue.
(a) Expression of SLC22A1 is significantly decreased in hepatocellular carcinoma (HCC) versus adjacent non-tumor tissue (P < 0.0001) and
individual paired results are given. For each patient, score values from both tissues are connected by a line. (b) Examples of different staining
intensities (0 = negative, 1 = low, 2 = medium, 3 = high) in non-tumor as well as HCC tissues. SLC22A1 was present in all non-tumor tissues. (c)
Exemplary weak immunohistochemical staining of SLC22A1 in two HCC samples is shown compared with strong staining in adjacent non-tumor
liver tissue. In addition, representative examples of SLC22A3 staining in HCC tissue as well as in adjacent non-tumor liver tissue is shown.
SLC22A1 and SLC22A3 are detected in the sinusoidal membrane of the hepatocytes (black arrows).
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used for immunostaining of SLC22A1. As shown in
Figure 2c, immunostaining in these samples clearly
demonstrates SLC22A3 expression at the protein level.
When we correlated the SLC22A1 immunoreactivity
score with clinicopathological characteristics, a signifi-
cant inverse correlation was found only for the MIB1/
Ki-67 proliferation rate (rs = -0.464, P < 0.0001), which
was determined in HCC tissue samples by immunohis-
tochemical staining as previously described (Figure S2A
in Additional file 1) [18]. Moreover, a significant differ-
ence in SLC22A1 expression between samples with low
(≤5%) and high (> 5%) proliferation rate was found (P =
0.01; Figure S2B in Additional file 1). In contrast, no
association was detected with etiological factors (for
example, hepatitis B virus or hepatitis C virus), age at
surgery or sex. Moreover, tumor grade or histological
stage was not significantly associated with SLC22A1
expression, although both stage 4 tumors revealed the
lowest levels of protein expression (Figure S3A,B in
Additional file 1).
DNA methylation of SLC22A1, SLC22A2 and SLC22A3 in
HCC and adjacent non-tumor tissues
To confirm the finding of a significantly lower expression
of SLC22A1 in HCC, mRNA levels of SLC22A1,
SLC22A2,a n dSLC22A3 were determined by real-time
PCR analysis in a cohort of 22 fresh-frozen HCC tissues
and adjacent non-tumor liver samples (HCC study popu-
lation set 2; Tables S1 and S3 in Additional file 1). More-
over, expression levels were compared with histologically
normal liver tissue from patients without primary liver
tumors (n = 100 pooled cDNAs, IKP-liver bank; Tables
S1 and S4 in Additional file 1). As shown in Figure 3a,
SLC22A1 mRNA expression in HCC samples was signifi-
cantly lower (P = 0.0007) compared with adjacent tissue.
Generally, SLC22A3 mRNA did not differ significantly
between HCC and adjacent tissue (Figure 3b). Again, the
SLC22A2 mRNA levels in HCC and adjacent tissue was
very low (data not shown).
To evaluate whether SLC22A1 is silenced in HCC due
to hypermethylation of SLC22A1 in tumor tissue, we stu-
died tissue-specific DNA methylation. DNA methylation
of SLC22A1, SLC22A2,a n dSLC22A3 gene promoters
was studied by gene-specific amplification of bisulfite-
treated DNA followed by in vitro transcription and
MALDI-TOF MS analysis [23,24]. The amplification
regions were designed to cover the surrounding 5’ UTRs
of the target genes. In addition, promoter regions were
analyzed in silico for the presence of CpG islands. In con-
trast to SLC22A2 and SLC22A3,n oC p Gi s l a n dw a sp r e -
dicted in the promoter region of SLC22A1,w h i c hi s
supported by genome-wide CpG island mapping analysis
[ 2 5 ] .W ew e r ea b l et oq u a n t i f y1 8C p Gs i t e sf o r
SLC22A1,6s i t e sf o rSLC22A2 and 57 sites for SLC22A3
(Table S5 in Additional file 1). As described in detail in
the additional methods in Additional file 1 the MALDI-
TOF MS method does not always allow detection of
methylation levels for each single CpG site [24], and
some of the methylation values represent the methylation
state of subsequent CpG sites. As shown in Figure 3c,
SLC22A1 methylation was significantly increased in HCC
tissues, consistent with the low level of mRNA expres-
sion. For both HCC and adjacent non-tumor liver tissue,
DNA methylation of SLC22A1 was highly variable
between individuals. In contrast, SLC22A3 methylation
was generally not different between HCC tissues and
adjacent non-tumor liver tissue (Figure 3d). DNA methy-
lation of SLC22A2 in HCC and adjacent non-tumor liver
tissue was high and showed low inter-individual variabil-
ity (Figure S4A in Additional file 1).
When we correlated DNA methylation with SLC22A1
mRNA expression in the total group of 22 HCC samples
(HCC study population, set 2; Tables S1 and S3 in Addi-
tional file 1), a significant inverse correlation between
SLC22A1 mRNA expression and individual CpG sites
within the SLC22A1 promoter region was found (Figure
3e; Table 1). There was no correlation between SLC22A1
mRNA expression and DNA methylation with clinico-
pathological variables like age at surgery, sex, tumor grade
and histological stage and tumor size (Figure S5A-D in
Additional file 1).
DNA methylation of SLC22A1, SLC22A2, and SLC22A3 in
histologically normal liver tissue
Generally, aberrant DNA methylation has been demon-
strated in tumor tissue and adjacent, histologically normal
tissue of tumor patients [26]. We therefore examined
SLC22A1, SLC22A2 and SLC22A3 DNA methylation in
histologically normal liver tissue from patients without pri-
mary liver tumors (n = 100, IKP-liverbank; Tables S1 and
S4 in Additional file 1) compared with histologically nor-
mal tissues derived from patients with HCC (n = 20;
Tables S1 and S4 in Additional file 1). Significantly higher
levels of methylation of SLC22A1 (Figures 4A and S6A
in Additional file 1), but not SLC22A3 (Figure S6C in
Additional file 1) were observed in adjacent tissue from
primary liver tumors (n = 20) compared with normal livers
without primary liver tumors (n =1 0 0 ) .T h eSLC22A2
gene region was again highly methylated (Figure S6B in
Additional file 1).
In summary, SLC22A1 DNA methylation was highest
in HCC tissue (HCC study population set 2) and
decreased progressively from adjacent to histologically
normal tissue of patients without primary liver tumors
from the IKP-liverbank (Figure 4a). Since a similar beha-
vior has been reported for the tumor suppressor gene
RASSF1A [27-29], DNA methylation levels of RASSF1A
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Figure 3 Expression and DNA methylation of SLC22A1 and SLC22A3 in hepatocellular carcinoma and adjacent non-tumor tissue. (a,b)
Quantitative mRNA expression of SLC22A1 (a) and SLC22A3 (b) in hepatocellular carcinoma (HCC), adjacent non-tumor tissue and histologically
normal liver tissue (pooled n = 100, IKP-liverbank). Data represent median and range. (c,d) DNA methylation profiles of SLC22A1 (c) and SLC22A3
(d) in HCC and adjacent non-tumor tissue. DNA methylation (y-axis) at each individual CpG site (x-axis) is given. Methylation profiles show
median levels (diamonds) at each CpG position (shaded areas are defined by 25%/75% quantiles). P-values are given for differences in
methylation level for CpG sites. *P < 0.05, **P < 0.01 are given on the x-axis. (e) Correlation of SLC22A1 mRNA expression in the 22 HCC samples
with DNA methylation of one individual CpG site (SLC22A1_02_CpG_5) in SLC22A1.
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Page 7 of 12were determined in our study. As indicated in Figure 4b,
we confirmed DNA hypermethylation of the tumor sup-
pressor gene RASSF1A in HCC samples of our study.
Comparable to our data on SLC22A1 methylation, DNA
methylation levels of RASSF1A were higher in HCC tis-
sue compared with adjacent non-tumor tissue (Figure
4b). However, in contrast to SLC22A1 (Figure 4a),
methylation of RASSF1A was not lower in histologically
normal tissue of patients without primary liver tumors
(n = 100) compared with normal tissues derived from
patients with HCC (n = 20, IKP-liverbank; Figure 4b).
To investigate whether DNA methylation status of
SLC22A1 and RASSF1A could effectively distinguish
HCC and histologically normal tissue, we determined
sensitivity and specificity (see statistical methods in
Additional file 1). The methylation levels of 11 selected
CpG sites in SLC22A1 and two in RASSF1A together
could classify HCC and normal tissues with 82%
Table 1 Correlation analysis of DNA methylation of individual CpG sites and SLC22A1 mRNA expression in
hepatocellular carcinoma
CpG sites Spearman’s correlation coefficient P-value Holm-adjusted P-value
SLC22A1_03_CpG_3 -0.274 0.217 0.652
SLC22A1_03_CpG_4_5 -0.221 0.323 0.652
SLC22A1_03_CpG_7 -0.425 0.048 0.247
SLC22A1_04_CpG_1 -0.525 0.012 0.110
SLC22A1_04_CpG_2 -0.451 0.035 0.247
SLC22A1_04_CpG_5 -0.381 0.080 0.321
SLC22A1_04_CpG_6 -0.129 0.568 0.652
SLC22A1_04_CpG_7 -0.590 0.004 0.039
SLC22A1_04_CpG_8.9.10 -0.462 0.030 0.242
SLC22A1_04_CpG_11 -0.451 0.035 0.247
SLC22A1_02_CpG_1 -0.709 0.0002 0.003
SLC22A1_02_CpG_2 -0.601 0.003 0.034
SLC22A1_02_CpG_3_4 -0.620 0.002 0.025
SLC22A1_02_CpG_5 -0.726 0.0001 0.002
P-values correspond to two-sided Spearman correlation tests.
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Figure 4 DNA methylation of SLC22A1 and RASSF1A in histologically normal liver tissue. (a,b) DNA methylation profiles of SLC22A1 (a) and
RASSF1A (b) in normal liver tissue (n = 100, IKP-liverbank), in histologically normal tissues derived from patients with hepatocellular carcinoma (HCC;
n = 20, adjacent to tumor) and in HCC tumor tissue (n = 22). DNA methylation (y-axis) at each individual CpG site (x-axis) is given. Methylation
profiles show median levels (diamonds) at each CpG position (shaded areas are defined by 25%/75% quantiles). P-values are given for differences in
methylation level for CpG sites between HCC (n = 22) and histologically normal liver tissue (n = 100). *P < 0.05, **P < 0.01.
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Page 8 of 12sensitivity and 96% specificity. For CpG sites of
RASSF1A alone, specificity was only 86% in contrast to
96% for CpG sites of SLC22A1. The sensitivity was simi-
lar (64%) for both genes.
Discussion
Altered expression of OCT transporters is important for
physiological processes and therapeutic responses to
drugs. Indeed, many clinically important drugs (for
example, metformin, cisplatin) are substrates for OCTs
[3-5,30]. Independent of genetic reasons for inter-indivi-
dual differences in SLC22A1 and SLC22A3 expression in
histologically normal liver tissue [20], there is first evi-
dence from microarray studies that SLC22A1 mRNA
expression is decreased in HCC [9-11]. This is supported
by our experiments using cDNAs from 381 human tissue
samples from 20 different tissues (Table S1 in Additional
file 1). SLC22A1 mRNA is expressed most prominently
in liver and at significantly lower levels in HCC tissues
(P = 0.029; Figure 1a), which corresponds with weaker
immunofluoresence staining by confocal laser scanning
microscopy. There are studies to suggest that SLC22A1 is
one of the most downregulated genes in HCC cells, with
a gene pattern correlated to poor prognosis [10,31,32].
SLC22A1 also is expressed differentially in EpCAM posi-
tive, stem-cell-like-HCC and EpCAM negative mature
hepatocyte-like HCC [33]. However, SLC22A1 protein
expression in HCC has so far not been studied systemati-
cally and the molecular mechanisms underlying the
tumor-specific expression of SLC22A1 are poorly
understood.
Therefore, we investigated first protein expression in a
set of 71 HCC tissues and adjacent non-tumor liver tissues
by semiquantiative immunohistochemistry. These experi-
ments indicated significantly decreased expression of
SLC22A1 protein in HCC (Figure 2a). When we correlated
SLC22A1 expression with clinicopathological characteris-
tics, the most striking result was a significant inverse cor-
relation between expression of SLC22A1 protein and the
tumor proliferation rate MIB1/Ki-67. Previous findings
support our observation since MIB1/Ki-67 staining is
reduced in protein kinase JNK
-/- knockout mice [34] and
microarray expression profiling clearly indicated that HCC
tissues with high activation status of JNK1 showed
reduced SLC22A1 mRNA expression and poorer prog-
nosis [10].
Since altered DNA methylation is a common mechan-
ism in tumor development, downregulation of SLC22A1
might be caused by hypermethylation of the SLC22A1
promoter region. This prompted us to systematically
quantify DNA methylation levels of SLC22A1, SLC22A2,
and SLC22A3 in the surrounding 5’ UTRs of the target
genes by MALDI-TOF MS. Consistent with both low
expression of mRNA and protein, SLC22A1 methylation
was significantly increased in HCC tissues compared
with adjacent non-tumor (Figure 3c) or non-tumor liver
tissues derived from patients without primary liver
tumors (Figure 4a). Methylation of SLC22A3 was gener-
ally not different.
Of note, altered methylation has been reported not
only for tumor tissue, but also for histologically normal
tissue adjacent to the tumor, and is supposed to be an
early and ubiquitous event in cancer development. Inter-
estingly, we found significantly higher levels of SLC22A1
methylation (Figure 4a) but not SLC22A3 methylation in
normal liver tissue adjacent to HCC tumors. This impor-
tant finding may explain the discrepancy between our
data and the results of Aoki et al.[ 1 6 ] ,w h or e p o r t e d
high methylation of SLC22A1 in a collection of 11 liver
samples. Since Aoki et al. used only tumor-free tissue
adjacent to HCC, these data strongly support our obser-
vation that SLC22A1 is hypermethylated in HCC and to a
lesser extent in the adjacent, histologically tumor-free
tissue.
Thus, based on our results, methylation of SLC22A1
decreased from high levels in HCC to lower levels in
adjacent, histologically normal liver and was lowest in
normal tissue from livers that were not derived from
patients with HCC (Figure 4a). The same methylation
pattern has been reported already for some tumor sup-
pressor genes like RASSF1A [27]. RASSF1A was the best
discriminator between HCC and tumor-free liver tissue
[35,36], which is confirmed by our data showing highest
methylation levels of RASSF1A in HCC compared with
adjacent tumor-free liver tissue. Since early detection of
aberrant DNA methylation might be beneficial for diag-
nosis of HCC, we suggest that SLC22A1 methylation
might be a new biomarker for the diagnosis of HCC or
for estimating risk for HCC in following patients at risk.
This idea is supported by the observation that the MIB1/
Ki-67 proliferation index correlated inversely with
SLC22A1 expression in our HCC cohort. Additional ana-
lysis of whether DNA methylation effectively discrimi-
nates between HCC and histologically normal liver tissue
indicated that the combination of the methylation status
of SLC22A1 and RASSF1A had a higher specificity and
sensitivity for this compared with each of the two mar-
kers alone. Further studies will be needed to verify these
data.
Several causes for aberrant DNA methylation in HCC
have been discussed. A recent study demonstrated that
the methylation state in specific genes in HCC is influ-
enced by viral infection or alcohol intake, thereby promot-
ing hepatocarcinogenesis [28]. Genome-wide methylation
analysis of human colon cancer showed that cancer-
related methylation changes occur predominately at sites
that distinguish normal tissues [37]. Interestingly, the
same region in the SLC22A1 gene that is differentially
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cific differences in SLC22A1 DNA methylation [38].
Since there is emerging evidence on the importance of
the location of CpG dinucleotide hypermethylation in
relation to gene expression but also clinicopathologic
characteristics of tumors, we next performed a systema-
tic correlation analysis between SLC22A1 mRNA expres-
sion and quantitative DNA methylation of individual
CpG sites within the SLC22A1 promoter region. Using
the total set of 22 fresh-frozen HCC tissues (Table S2 in
Additional file 1), the CpG sites in SLC22A1 with the
strongest inverse correlation with mRNA expression in
HCC (Table 1) were remarkably located upstream of the
translational start site in exon 1. However, the overall
methylation profile for the total SLC22A1 region investi-
gated in our study was quite similar. The underlying
mechanism for this phenomenon is unknown, but
recent findings indicate that especially DNA methylation
of the first exon correlates with transcriptional silencing
[39]. Thus, DNA methylation within the first exon may
block effective transcription.
Since OCTs are important targets for various thera-
peutic agents, such as metformin or the platinum drugs
cisplatin or picoplatin [30,40,41], the finding that
SLC22A1 is downregulated in liver cancer due to hyper-
methylation may be important for alternative therapeu-
tic approaches for treatment of HCC. We speculate that
DNA methylation of SLC22A1 in human liver contri-
butes to differences in drug response for drugs that are
substrates of SLC22A1. By contrast with genetic var-
iants, epigenetic modifications are reversible, which
offers the possibility to modulate the expression of
genes with demethylating agents (for example, decita-
bine). As a consequence, for instance, pretreatment with
decitabine may increase the intracellular concentration
of the SLC22A1 substrate cisplatin, thereby resulting in
enhanced cytotoxicity. Of course, treatment with decita-
bine will not only lead to re-expression of OCTs and
additional factors might be important for cisplatin effi-
cacy, for example, the expression of the copper trans-
porter CTR1, which alters sensitivity to cisplatin [42]. In
addition, demethylation may impair expression of efflux
transporters, thereby leading to an enhanced efflux and
chemoresistance (reviewed in [43]). For instance, the
promoter of the efflux transporter gene ABCB1,e n c o d -
ing P-glycoprotein, is hypomethylated in several cancer
cell lines, thereby leading to a multidrug-resistance phe-
notype compared to drug-sensitive cell lines [44]. More-
over, the effect of decitabine treatment might lead to
increased risk of cisplatin cytotoxicity in other organs,
since the demethylating effect is not restricted to liver
tissue.
Our study has some limitations that need to be con-
sidered. First, our study design of HCC samples was
retrospective and, for instance, confounding of SLC22A1
expression cannot be excluded with certainty. Second,
the number of HCC samples was small, and the rele-
vance of the correlation analyses of distinct clinico-
pathological factors (for example, tumor stage,
histological grade) with DNA methylation or expression
is thus limited and needs further study. Nevertheless,
our findings indicate for the first time that downregula-
tion of the uptake transporter SLC22A1 in HCC is asso-
ciated with DNA methylation as an epigenetic
phenomenon. This finding has potential consequences
for the diagnosis of HCC and for future therapeutic
concepts.
Conclusions
SLC22A1 protein expression is significantly decreased in
HCC compared with tumor-free adjacent liver tissue.
DNA hypermethylation of individual CpG sites within
the SLC22A1 gene is associated with downregulation of
SLC22A1 expression in HCC. Moreover, SLC22A1
methylation decreased from high levels in HCC to lower
levels in histological tumor-free adjacent liver tissue and
was lowest in tumor-free liver tissue not derived from
patients with HCC. Therefore, early detection of aber-
rant DNA methylation of SLC22A1 might be beneficial
for the diagnosis of HCC or for estimating risk for HCC
in following patients at risk. Since platinum drugs are
substrates of SLC22A1, the modulation of gene expres-
sion by pretreatment with demethylating agents may
offer novel therapeutic options in HCC, which has to be
proven in further studies.
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